Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine + triamcinolone acetonide (Rutgers University)
- Development stage
- Unknown
- Lead developer
- Rutgers University
- Modality
- Small Molecules
- Administration
- Percutaneous
01
Overview
This combination therapy consists of bupivacaine, a long-acting local anesthetic, and triamcinolone acetonide, a synthetic corticosteroid. It is administered as a superior laryngeal nerve (SLN) block during microdirect laryngoscopy for benign vocal fold lesions, such as polyps and cysts. Bupivacaine acts by blocking voltage-gated sodium channels, thereby inhibiting nerve impulse conduction and providing regional anesthesia. Triamcinolone acetonide acts as a glucocorticoid receptor agonist, exerting anti-inflammatory effects to reduce postoperative edema and irritation. The combination is being evaluated by Rutgers University to improve patient outcomes, specifically by reducing postoperative pain and coughing while improving voice recovery.
- Brand names
- MarcaineKenalog-40Kenalog40Kenalog 40
- Other names
- Superior laryngeal nerve blockSLN block
02
Targets
Prostanoid R (Prostanoid receptors)SPHK2 (Sphingosine kinase 2)SCN5A (Sodium channel protein type 5 subunit alpha)GR (Glucocorticoid receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on bupivacaine + triamcinolone acetonide (Rutgers University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine + triamcinolone acetonide (Rutgers University).